Saltar al contenido
PivotalWire
Domingo 22 nov 2026SEC · NASDAQ biomédico

Calendario›SNY›Vakzimeter RSV

Vakzimeter RSV

Ensayo de Sanofi en Respiratory Syncytial Virus Immunization (del registro, en inglés).

Fase
no aplica
Estado
Completado
Participantes
2.400
previstos
Centros
1
Fin del objetivo primario
may 2026
fecha real

Título oficial en el registro (en inglés): Repeated Cross Sectional Surveillance Study To Determine the Respiratory Syncytial Virus (RSV) Immunization Rates in German Infants

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en ene 2025.

De principio a fin

  1. Empieza el ensayo (ene 2025)
  2. Lectura de resultados may 2026 (real)
  3. Hoy

Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.

Qué mide

Assessing the nirsevimab immunization rates among eligible infants in both cohorts (Throughout Study (Approximatley 4 months)) (del registro, en inglés)

Qué se prueba

Se mide la tasa de inmunización con Nirsevimab en lactantes elegibles durante su primera temporada de RSV en Alemania.

Lo que dice el documentoThe primary objective of this study is to determine the Nirsevimab immunization rate in eligible infants in their first RSV-season in Germany. The study will focus on: 1.

Traducción automática (claude-haiku-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.

Cómo lo describe el promotor

En el documentoEn inglés, del registroIn June 2024, the German Standing Committee on Vaccination (STIKO) recommended the universal immunization of infants with nirsevimab during their first RSV season. Nirsevimab is a long-acting monoclonal antibody designed to provide passive immunity against RSV, significantly reducing the risk of severe RSV disease in infants. This recommendation marks the 2024/25 season as the first in which nirsevimab is broadly implemented for all infants in Germany. Despite the introduction of this new prevention measure, there is currently no timely monitoring system for immunization rates. Understanding the uptake and coverage of nirsevimab is crucial for evaluating its impact on public health and guiding future vaccination strategies. Therefore, this study aims to monitor the national immunization rates of nirsevimab in children under one year of age during the initial seasons of its widespread use. The primary objective of this study is to determine the Nirsevimab immunization rate in eligible infants in their first RSV-season in Germany. The study will focus on: 1. Assessing the immunization rates among eligible infants (according to STIKO recommendation) in their first RSV-season in Germany (i.e. across all geographies) 2. Assessing the immunisation rates among the "catch-up cohort", i.e. all infants born between April and September. For these infants, the STIKO recommends immunization with nirsevimab in early autumn. 3. Assessing the immunization rate among the "in-season cohort", i.e. all infants born during the RSV season between October and March. For these newborns, the STIKO recommends immunization with Nirsevimab shortly after birth, preferably during the second "well-baby visit" at the age of 3-10 days of life.

Más ensayos de SNY

EnsayoFaseEstadoLectura de resultados
Avalglucosidase alfa · Mini-COMETFase 2En marcha, sin reclutarsep 2019 (real)
Yellow fever vaccineFase 2En marcha, sin reclutarmay 2022 (real)
Yellow fever vaccine · VYF02Fase 2En marcha, sin reclutarjun 2022 (real)
SAR441344 IVFase 2En marcha, sin reclutarsep 2022 (real)
Meningococcal PolysaccharideFase 3En marcha, sin reclutarmar 2023 (real)
rilzabrutinib · LUMINA 2Fase 2En marcha, sin reclutarmay 2024 (real)

Todos los de SNY, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06824207), actualizada en jun 2026.